Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H20N4O2S |
Molecular Weight | 356.442 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=C(C=CC=C2N1S(=O)(=O)C3=CC=CC=C3)N4CCNCC4
InChI
InChIKey=MAYQIFVKVAUMPD-UHFFFAOYSA-N
InChI=1S/C18H20N4O2S/c1-14-20-18-16(21-12-10-19-11-13-21)8-5-9-17(18)22(14)25(23,24)15-6-3-2-4-7-15/h2-9,19H,10-13H2,1H3
Molecular Formula | C18H20N4O2S |
Molecular Weight | 356.442 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:05:31 GMT 2023
by
admin
on
Sat Dec 16 12:05:31 GMT 2023
|
Record UNII |
4JEH3BL51N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1226793-34-5
Created by
admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545344
Created by
admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
|
PRIMARY | |||
|
46203710
Created by
admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
|
PRIMARY | |||
|
300000041347
Created by
admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
|
PRIMARY | |||
|
4JEH3BL51N
Created by
admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
TARGET -> INHIBITOR |
Full antagonist SAM-760 completed phase I trials with no adverse effects at doses of up to 50 mg daily. Pfizer terminated a phase II trial after SAM-760 30 mg/day failed to produce an improvement in cognition in patients already taking a stable dose of donepezil.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |